Abstract:BACKGROUND:Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood.METHODS:For a comprehensive analysis of the tumor microenvironment in cholangiocarcinoma, we performed multiplex immunohistochemistry with two 15-marker immune panels and Nanostring assays for a comprehensive analysis of 104 surgically resected cholangiocarcinomas including intrahepatic, hilar, and distal cholangiocarcinoma. We also validated some key findings with a batch integration analysis of published single cell RNA sequencing data.RESULTS:This study found that natural killer cells occupy the largest immune cell compartment in cholangiocarcinoma. Granzyme-B+CD8+ effector T cells are significantly associated with better overall survival in both intrahepatic and distal cholangiocarcinoma. Above 85% of intrahepatic cholangiocarcinomas with higher density of PD-1-EOMES-CD8+ effector T cells are associated with long-term survival. However, only the density of PD-1-EOMES-CD8+ T cells in the tumor areas, but not in the peripheries of the tumors, is prognostic. In all three cholangiocarcinoma subtypes, T regulator cells are significantly associated with a poor prognosis; however, M1 and M2 tumor-associated macrophages or PD-L1+ tumor-associated macrophage demonstrate different prognostic values. Combining PD-L1+ M1 or M2, PD-L1- M1 or M2 tumor-associated macrophages, and T regulator cells to subgroup intrahepatic and distal cholangiocarcinoma, the prognosis is significantly better distinguished. Moreover, PD-L1- M2 tumor-associated macrophages is associated with a good prognosis in intrahepatic and distal cholangiocarcinoma, suggesting this subtype of M2 tumor-associated macrophages may be antitumoral. Interestingly, lower densities of various types of immunosuppressive cells are associated with decreased infiltration of effector T cells in distal and hilar cholangiocarcinoma, but not in intrahepatic cholangiocarcinoma. In intrahepatic cholangiocarcinoma, PD-L1+ tumor-associated macrophages exert their immunosuppressive function likely through promoting T cell exhaustion.CONCLUSIONS:This study suggests that the densities of Granzyme-B+CD8+ effector T cells and non-exhausted PD-1-EOMES-CD8+ T cells and the PD-L1 status in the tumor-associated macrophages are prognostic makers in cholangiocarcinomas. The study also supports targeting PD-L1+ tumor-associated macrophages as the immunotherapy for cholangiocarcinoma.

Molecular profiling reveals potential targets in cholangiocarcinoma

Molecular Profiling and Prognostic Analysis in Chinese Cholangiocarcinoma: an Observational, Retrospective Single-Center Study.

Survival analysis of genome-wide profiles coupled with Connectivity Map database mining to identify potential therapeutic targets for cholangiocarcinoma

Five Hub Genes Can Be the Potential DNA Methylation Biomarkers for Cholangiocarcinoma Using Bioinformatics Analysis

Transcriptomic Analysis and Identification of Prognostic Biomarkers in Cholangiocarcinoma

Proteogenomic Characterization of Cholangiocarcinoma

Screening and Identification of Genes Associated with Cell Proliferation in Cholangiocarcinoma.

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

Investigation of transcriptional and immunological disparities among patient groups with varied prognostic risk factors in cholangiocarcinoma

Characteristic Analysis of Featured Genes Associated with Cholangiocarcinoma Progression

Immune Cell Atlas of Cholangiocarcinomas Reveals Distinct Tumor Microenvironments and Associated Prognoses.

Comprehensive Molecular Profiling of Extrahepatic Cholangiocarcinoma in Chinese Population and Potential Targets for Clinical Practice

Identification of prognostic biomarkers for cholangiocarcinoma by combined analysis of molecular characteristics of clinical MVI subtypes and molecular subtypes

Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing

Specific Genomic Alterations and Prognostic Analysis of Perihilar Cholangiocarcinoma and Distal Cholangiocarcinoma.

Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression

Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies

Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma

Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches

Unveiling the Immunogenomic Landscape of Cholangiocarcinoma: Identifying New Prognostic Markers and Therapeutic Targets Based on CCL5 Expression.

Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities